News

Video

Frontline Therapy for Renal Cell Carcinoma: Choosing the Right Regimen

Author(s):

Ulka Vaishampayan, MDAlan Tan, MD

Oncologists discuss the selection of the optimal frontline therapy for renal cell carcinoma, considering factors like response rates, progression, quality of life, and long-term results.

Related Videos
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Naval G. Daver, MD
Jason Abdou Mouabbi, MD, assistant professor, Department of Breast Medical Oncology, Department of General Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
Elias Jabbour, MD,
Ibrahim T. Aldoss, MD
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
Shubham Pant, MD, MBBS
Related Content
Jan A. Burger, MD, PhD
July 25th 2024

Time-Limited Acalabrutinib/Obinutuzumab Produces Durable Responses in Treatment-Naive CLL

Robert Z. Orlowski, MD, PhD, Florence Maude Thomas Cancer Research Professorship, Department of Lymphoma/Myeloma, director, Section of Myeloma, professor, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
July 11th 2024

Orlowski on Isa-VRd in Transplant-Ineligible Multiple Myeloma

V. Craig Jordan, PhD
July 22nd 2024

V. Craig Jordan, PhD, the ‘Father of Tamoxifen,’ Dies at 76

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Guillermo Garcia-Manero, MD
July 17th 2024

Real-World and Post-Hoc Analyses Support Luspatercept Use in Low-Risk Myelodysplastic Syndrome

Neil D. Gross, MD, FACS
July 10th 2024

Neoadjuvant Cemiplimab Underscores Push to Bolster Treatment of CSCC